| # | Title | Journal | Year | Citations |
|---|
| 1 | Phosphorothioates, Essential Components of Therapeutic Oligonucleotides | Nucleic Acid Therapeutics | 2014 | 457 |
| 2 | GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics | Nucleic Acid Therapeutics | 2018 | 388 |
| 3 | Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility | Nucleic Acid Therapeutics | 2018 | 335 |
| 4 | FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga | Nucleic Acid Therapeutics | 2017 | 284 |
| 5 | Molecular Mechanisms of Antisense Oligonucleotides | Nucleic Acid Therapeutics | 2017 | 255 |
| 6 | RNA Sequencing: Platform Selection, Experimental Design, and Data Interpretation | Nucleic Acid Therapeutics | 2012 | 207 |
| 7 | Polymers in Small-Interfering RNA Delivery | Nucleic Acid Therapeutics | 2011 | 182 |
| 8 | CpG Still Rocks! Update on an Accidental Drug | Nucleic Acid Therapeutics | 2012 | 171 |
| 9 | Long Non-Coding RNAs: Challenges for Diagnosis and Therapies | Nucleic Acid Therapeutics | 2013 | 163 |
| 10 | FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides | Nucleic Acid Therapeutics | 2017 | 144 |
| 11 | Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues | Nucleic Acid Therapeutics | 2017 | 144 |
| 12 | Journey of siRNA: Clinical Developments and Targeted Delivery | Nucleic Acid Therapeutics | 2018 | 135 |
| 13 | Uniqueness, Advantages, Challenges, Solutions, and Perspectives in Therapeutics Applying RNA Nanotechnology | Nucleic Acid Therapeutics | 2012 | 108 |
| 14 | Rational Truncation of an RNA Aptamer to Prostate-Specific Membrane Antigen Using Computational Structural Modeling | Nucleic Acid Therapeutics | 2011 | 106 |
| 15 | Characterization of Target mRNA Reduction Through In Situ RNA Hybridization in Multiple Organ Systems Following Systemic Antisense Treatment in Animals | Nucleic Acid Therapeutics | 2013 | 106 |
| 16 | Aptamer-Mediated Delivery of Splice-Switching Oligonucleotides to the Nuclei of Cancer Cells | Nucleic Acid Therapeutics | 2012 | 104 |
| 17 | Fit for the Eye: Aptamers in Ocular Disorders | Nucleic Acid Therapeutics | 2016 | 103 |
| 18 | The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials | Nucleic Acid Therapeutics | 2017 | 101 |
| 19 | Cellular Uptake and Intracellular Trafficking of Oligonucleotides: Implications for Oligonucleotide Pharmacology | Nucleic Acid Therapeutics | 2014 | 99 |
| 20 | Co-Injection of a Targeted, Reversibly Masked Endosomolytic Polymer Dramatically Improves the Efficacy of Cholesterol-Conjugated Small Interfering RNAsIn Vivo | Nucleic Acid Therapeutics | 2012 | 98 |
| 21 | Effect of Chemical Modifications on Aptamer Stability in Serum | Nucleic Acid Therapeutics | 2017 | 97 |
| 22 | Chemical Modification Study of Antisense Gapmers | Nucleic Acid Therapeutics | 2012 | 96 |
| 23 | Intracellular Trafficking and Endosomal Release of Oligonucleotides: What We Know and What We Don’t | Nucleic Acid Therapeutics | 2018 | 94 |
| 24 | MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct | Nucleic Acid Therapeutics | 2018 | 93 |
| 25 | Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study | Nucleic Acid Therapeutics | 2020 | 93 |
| 26 | A Locked Nucleic Acid Oligonucleotide Targeting MicroRNA 122 Is Well-Tolerated in Cynomolgus Monkeys | Nucleic Acid Therapeutics | 2012 | 91 |
| 27 | Improving siRNA DeliveryIn VivoThrough Lipid Conjugation | Nucleic Acid Therapeutics | 2018 | 90 |
| 28 | Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience | Nucleic Acid Therapeutics | 2019 | 85 |
| 29 | In Vitro Selection of RNA Aptamer and Specific Targeting of ErbB2 in Breast Cancer Cells | Nucleic Acid Therapeutics | 2011 | 83 |
| 30 | A Chemical View of Oligonucleotides for Exon Skipping and Related Drug Applications | Nucleic Acid Therapeutics | 2014 | 83 |
| 31 | The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy | Nucleic Acid Therapeutics | 2020 | 82 |
| 32 | Toxicological and Pharmacokinetic Properties of Chemically Modified siRNAs Targeting p53 RNA Following Intravenous Administration | Nucleic Acid Therapeutics | 2012 | 81 |
| 33 | Hepatotoxic Potential of Therapeutic Oligonucleotides Can Be Predicted from Their Sequence and Modification Pattern | Nucleic Acid Therapeutics | 2013 | 80 |
| 34 | Current Challenges in Delivery and Cytosolic Translocation of Therapeutic RNAs | Nucleic Acid Therapeutics | 2018 | 78 |
| 35 | Potent Antibacterial Antisense Peptide–Peptide Nucleic Acid Conjugates AgainstPseudomonas aeruginosa | Nucleic Acid Therapeutics | 2012 | 77 |
| 36 | Exon-Skipping Antisense Oligonucleotides to Correct Missplicing in Neurogenetic Diseases | Nucleic Acid Therapeutics | 2014 | 77 |
| 37 | Preclinical Evaluation of the Toxicological Effects of a Novel Constrained Ethyl Modified Antisense Compound Targeting Signal Transducer and Activator of Transcription 3 in Mice and Cynomolgus Monkeys | Nucleic Acid Therapeutics | 2013 | 73 |
| 38 | Toxicological and Pharmacokinetic Properties of QPI-1007, a Chemically Modified Synthetic siRNA Targeting Caspase 2 mRNA, Following Intravitreal Injection | Nucleic Acid Therapeutics | 2014 | 72 |
| 39 | Evaluation and Reduction of CRISPR Off-Target Cleavage Events | Nucleic Acid Therapeutics | 2019 | 71 |
| 40 | Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment | Nucleic Acid Therapeutics | 2019 | 70 |
| 41 | Extensive and Prolonged Restoration of Dystrophin Expression with Vivo-Morpholino-Mediated Multiple Exon Skipping in Dystrophic Dogs | Nucleic Acid Therapeutics | 2012 | 69 |
| 42 | Aptamer-Mediated Delivery of Chemotherapy to Pancreatic Cancer Cells | Nucleic Acid Therapeutics | 2012 | 67 |
| 43 | Impurities in Oligonucleotide Drug Substances and Drug Products | Nucleic Acid Therapeutics | 2017 | 67 |
| 44 | In Vitro Selection of Modified RNA Aptamers Against CD44 Cancer Stem Cell Marker | Nucleic Acid Therapeutics | 2013 | 64 |
| 45 | The Interaction of Telomeric DNA and C-myc22 G-Quadruplex with 11 Natural Alkaloids | Nucleic Acid Therapeutics | 2012 | 58 |
| 46 | Digital Quantitation of Potential Therapeutic Target RNAs | Nucleic Acid Therapeutics | 2013 | 58 |
| 47 | Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial | Nucleic Acid Therapeutics | 2022 | 58 |
| 48 | Nucleotide Bias Observed with a Short SELEX RNA Aptamer Library | Nucleic Acid Therapeutics | 2011 | 57 |
| 49 | Argonaute and the Nuclear RNAs: New Pathways for RNA-Mediated Control of Gene Expression | Nucleic Acid Therapeutics | 2012 | 57 |
| 50 | siRNA Delivery to the Glomerular Mesangium Using Polycationic Cyclodextrin Nanoparticles Containing siRNA | Nucleic Acid Therapeutics | 2015 | 57 |
